CD5 and diffuse large B-cell lymphoma: Patients with CD5+ DLBCL had a significantly poorer prognosis than those with CD5- DLBCL (Figure 1) [median OS: 13.7 months vs. not reached, P = 0.0117, hazard ratio (HR): 3.082 (95% CI: 0.1320–0.7756); median progression-free survival (PFS): 9.85 months vs. not reached, P = 0.0039, HR: 3.474 (95% CI: 0.1242–0.6707)].